Olesoxime + Placebo Comparator + Riluzole
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis
Conditions
Amyotrophic Lateral Sclerosis
Trial Timeline
Apr 30, 2009 → Sep 30, 2011
NCT ID
NCT00868166About Olesoxime + Placebo Comparator + Riluzole
Olesoxime + Placebo Comparator + Riluzole is a phase 3 stage product being developed by Roche for Amyotrophic Lateral Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00868166. Target conditions include Amyotrophic Lateral Sclerosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00868166 | Phase 3 | Completed |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 44 |
| 89Zr-DFO-AP-101 | Eli Lilly | Phase 1 | 33 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 52 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 23 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 65 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 65 |
| methylcobalamin + saline solution | Eisai | Phase 3 | 77 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2506PO + ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 52 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 33 |
| TCH346 | Novartis | Phase 2 | 52 |
| VHB937 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| BLZ945 | Novartis | Phase 2 | 52 |
| TRO19622 | Roche | Phase 2/3 | 65 |
| Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) | Pfizer | Phase 1/2 | 40 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 51 |
| DNL747 + Placebo | Sanofi | Phase 1 | 32 |